Renal Cancer - Results from #800

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. August 10, 2023

Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center. August 10, 2023

Demographic Patterns and Clinicopathological Analysis of Sarcomatoid Renal Cell Carcinoma in US Population. August 9, 2023

Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. August 9, 2023

Cellular and Molecular Features of Clear-Cell Renal Cell Carcinoma Tumors - Expert Commentary August 8, 2023

Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker. August 8, 2023

Chromophobe renal cell carcinoma. August 8, 2023

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Pla August 8, 2023

Partial versus radical nephrectomy for complex renal mass: multicenter comparative analysis of functional outcomes (Rosula collaborative group). August 7, 2023

Role of perioperative immunotherapy in localized renal cell carcinoma. August 7, 2023

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. August 4, 2023

Computer tomography-based shape of tumor contour and texture of tumor heterogeneity are independent prognostic indicators for clinical T1b-T2 renal cell carcinoma. August 4, 2023

Retroperitoneal vs. transperitoneal robotic partial nephrectomy: a multicenter propensity-score matching analysis (PADORA Study - UroCCR n° 68). August 4, 2023

Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma? August 3, 2023

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. August 3, 2023

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. August 2, 2023

Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses? August 2, 2023

AI-generated R.E.N.A.L.+ score surpasses human-generated score in predicting renal oncologic outcomes. August 1, 2023

"Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC-mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas: Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications. August 1, 2023

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma. July 31, 2023

Page 41 of 456